week 62 check-in — 12kg down, fatigue manageable, one thing confusing me
week 62 check-in — 12kg down, fatigue manageable, one thing confusing me. Same spreadsheet I have been keeping since the start, nothing retrofitted.
Pulling the figures out of the title: week 62 and 12kg. All of it is written down as it happened rather than reconstructed.
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.
Trial names corrected in the title. The phase 3 programme and the phase 2 readout are not the same thing.
[deleted]
comparing reta phase 2 to sema phase 3 is comparing different things
the escalation is where most of the reported trouble sits